Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» renal cell carcinoma
renal cell carcinoma
Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
Mon, 02/11/19 - 08:24 pm
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Wed, 09/19/18 - 11:27 am
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Exelixis Gets the Patients Eventually
Motley Fool
Mon, 08/6/18 - 11:47 pm
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
CP Wire
Wed, 06/6/18 - 09:42 am
Peloton Therapeutics
renal cell carcinoma
PT2977
Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer
Wed, 06/6/18 - 09:33 am
Peloton Therapeutics
renal cell carcinoma
PT2977
Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Forbes
Sun, 06/3/18 - 10:00 am
Nektar
Bristol-Myers Squibb
NKTR-214
ASCO 2018
melanoma
renal cell carcinoma
urothelial cancer
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Thu, 05/17/18 - 09:42 am
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Fierce Pharma
Thu, 04/12/18 - 11:46 am
Pfizer
renal cell carcinoma
kidney cancer
Inlyta
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
CP Wire
Tue, 04/10/18 - 03:21 pm
Pfizer
renal cell carcinoma
Inlyta
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Tue, 04/10/18 - 02:44 pm
Pfizer
renal cell carcinoma
Inlyta
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Thu, 01/4/18 - 10:04 pm
Exelixis
Cabometyx
renal cell carcinoma
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Fri, 08/18/17 - 12:01 am
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Wed, 07/12/17 - 10:05 am
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Here's Why AVEO Oncology Fell as Much as 12.7% Today
Motley Fool
Tue, 07/11/17 - 11:51 pm
Aveo Oncology
tivozanib
renal cell carcinoma
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug
Xtalks
Thu, 06/15/17 - 09:39 am
Acceleron
renal cell carcinoma
clinical trials
Axitinib
Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis
Endpoints
Wed, 02/22/17 - 09:49 am
Argos
personalized medicine
vaccines
rocapuldencel-T
renal cell carcinoma
5 Reasons Exelixis's Cabometyx Is Set To Be The Next Blockbuster Opportunity
Seeking Alpha
Thu, 11/10/16 - 10:59 am
Exelixis
Cabometyx
renal cell carcinoma
These 3 Little Biotechs Just Scored Big
Motley Fool
Tue, 10/11/16 - 09:33 pm
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
AVEO Collaborates With Bristol-Myers Squibb for RCC Drug
Investopedia
Fri, 09/23/16 - 09:43 am
Aveo Pharmaceuticals
Bristol-Myers Squibb
renal cell carcinoma
tivozanib
Pages
« first
‹ previous
1
2
3
4
next ›
last »